drugset / Trial / NCT07025512
177Lu-PSMA-617 in Metastatic Castration Resistant Prostate Cancer (mCRPC) With Bone Marrow Involvement and Cytopenia
NaSingle-groupOpen-labelTreatment
Summary
The purpose of the study is to examine the clinical and biological effects of 177Lu-PSMA-617 in mCRPC patients with cytopenia\[s\].
Timeline
- Start
- 2025-08-03
- Primary completion
- 2026-05-04
- Completion
- 2026-05-04
Outcome
Outcome not reported
Stopped: “PI requested”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | 177Lu-PSMA-617 | Other / unclassified | — | Intravenous |